Equivocal results from its first pivotal Phase III trial with OMS103HP in knee surgery shaved Omeros Corp.'s stock, but gave the company a roadmap for the next study, which will use postoperative pain – a secondary endpoint, met in the latest experiment – as the primary outcome goal. Read More
Galera Therapeutics Inc., a 2009 start-up based on the approach of treating disease by targeting superoxide, came out of stealth mode in December with a new CEO and a Series A financing of $11 million. Read More
Chemotherapy combinations, Michael Hemann told BioWorld Today, are currently determined in "a process of trial and error that has no fundamental logic, other than trying to give patients drugs that do not have the same side effects." Read More
More than 40 years after it was first proposed, a single European patent will come into effect on Jan. 1, 2014, after a compromise deal was endorsed last month. Read More
• K-V Pharmaceutical Co., of St. Louis, said the U.S. Bankruptcy Court for the Southern District of New York approved its settlement agreement with Hologic Inc., of Bedford, Mass., and authorized the company to enter into an $85 million debtor-in-possession (DIP) financing to fund the settlement and other business matters. Read More
• Synergy Pharmaceuticals Inc., of New York, completed a Phase I single-ascending dose trial of SP-333 for ulcerative colitis and other gastrointestinal diseases. The placebo-controlled, dose-escalating trial assessed safety and pharmacodynamics in eight volunteer cohorts, dosed from 0.1 mg to 60 mg. Read More
A team from the German Technical University of Munich has added to the evidence that stem cell-like properties can be gained and lost by multiple cell types during tumor development. Read More
